EP
GNMK

Eversept Partners’s GenMark Diagnostics, Inc GNMK Stock Holding History

Eversept Partners’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-524,257
Closed -$2.16M – 83
2020
Q1 		$2.16M Buy
+524,257
New +$2.46M 0.54% 28

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Eversept Partners's GNMK Position: Q2 2020 in Review

Eversept Partners sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2020, closing a stake of 524,257 shares — an estimated $2.16M sold.

Eversept Partners first reported a position in GNMK in Q1 2020 and held it in 1 quarter. The position peaked at $2.16M in Q1 2020. 148 funds tracked by Wall St. Rank hold GNMK as of Q2 2020.

  • Eversept Partners reported no remaining GenMark Diagnostics, Inc position as of Q2 2020 after selling out during the quarter.
  • Eversept Partners sold 524,257 GenMark Diagnostics, Inc shares in Q2 2020, an estimated $2.16M.
  • Eversept Partners first reported a position in GenMark Diagnostics, Inc in Q1 2020 and held it in 1 quarter.
  • Eversept Partners's GenMark Diagnostics, Inc position peaked at $2.16M in Q1 2020.
  • 148 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2020.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.